EnPlusOne Biosciences Secures $10M to Revolutionize RNA Therapeutics with ezRNA™ Platform

EnPlusOne Biosciences, a pioneering force in the biotech industry, proudly announced today that it has raised $10,000,000 in new funding. This funding milestone marks a pivotal moment for the company as it continues its mission to bring innovative RNA and RNA solutions to the world. At the core of EnPlusOne’s breakthrough is its proprietary ezRNA™ synthesis platform—a stepwise innovation designed to incorporate a diverse array of nucleotide modifications. This cutting-edge technology not only promises efficiency and precision in direct RNA synthesis but also supports a wide variety of RNA solution applications, paving the way for sustained therapeutic RNA manufacture at commercial scales. The new capital injection will be strategically deployed to accelerate the development and scale-up of the ezRNA™ platform, ensuring that the manufacturing process remains both sustainable and adaptable to the rapidly evolving demands of modern medicine. In addition to fueling further research and development efforts, the funds will help expand production capabilities and foster collaborations with key industry partners, ultimately broadening the application spectrum of RNA-based therapies. This initiative underscores EnPlusOne’s commitment to revolutionizing how therapeutic RNA is produced and delivered, making it a critical enabler for next-generation biomedical and pharmaceutical advancements. As the company charts its ambitious course toward a future where RNA solutions are accessible on a global scale, stakeholders and partners alike can expect continued innovation and transformative impact. For more detailed information about EnPlusOne Biosciences and the groundbreaking ezRNA™ technology, please visit www.enplusonebio.com.